Author

Paul Lancett

Observed names: P. Lancett, Paul Lancett (1270968)

Observed institutions: University of Oxford, Prolysis (United Kingdom), Evotec (United Kingdom)

OpenAlex ID: A5083442179

Creating an Antibacterial with in Vivo Efficacy: Synthesis and Characterization of Potent Inhibitors of the Bacterial Cell Division Protein FtsZ with Improved Pharmaceutical Properties

2010 · David J. Haydon, James M. Bennett, et al. · Journal of Medicinal Chemistry · 109

Design, synthesis and structure–activity relationships of substituted oxazole–benzamide antibacterial inhibitors of FtsZ

2013 · Neil R. Stokes, Nicola Baker, et al. · Bioorganic & Medicinal Chemistry Letters · 82

DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity

2008 · Stephen P. East, Clara Bantry White, et al. · Bioorganic & Medicinal Chemistry Letters · 73

Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors

2013 · Lorraine C. Axford, Piyush K. Agarwal, et al. · Bioorganic & Medicinal Chemistry Letters · 39

Biological Evaluation of Benzothiazole Ethyl Urea Inhibitors of Bacterial Type II Topoisomerases

2013 · Neil R. Stokes, Helena B. Thomaides-Brears, et al. · Antimicrobial Agents and Chemotherapy · 34

Discovery and in vivo evaluation of alcohol-containing benzothiazoles as potent dual-targeting bacterial DNA supercoiling inhibitors

2014 · James T. Palmer, Lorraine C. Axford, et al. · Bioorganic & Medicinal Chemistry Letters · 21

Development and Characterization of a Human Hepatocyte Low Intrinsic Clearance Assay for Use in Drug Discovery

2018 · Paul Lancett, Beth Williamson, et al. · Drug Metabolism and Disposition · 18

Corrigendum to “DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity” [Bioorg. Med. Chem. Lett. 19 (2009) 894]

2009 · Stephen P. East, Clara Bantry White, et al. · Bioorganic & Medicinal Chemistry Letters · 2

Application of a low intrinsic clearance assay in preclinical drug discovery

2018 · Beth Williamson, Paul Lancett, et al. · Drug Metabolism and Pharmacokinetics

P791 Novel small-molecule inhibitors of gyrase B: antibacterial activity in vitro and in murine models of infection

2007 · D. Haydon, P. Lancett, et al. · International Journal of Antimicrobial Agents

Works count: 11

Citation count: 378

H-index: 7

I10-index: 7